STAT+: Abivax has still not been acquired. What’s going on? — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Abivax is a French drugmaker developing obefazimod, a treatment for ulcerative colitis that the article describes as having blockbuster commercial potential.
- Abivax remains unbetrothed even as biotech M&A activity is described as being off the charts.
- Abivax was widely expected to be taken out for about $20 billion, give or take a few billion, nine months into the year, with a deal deemed likely any day.
- Abivax’s lack of an acquisition has caused its stock’s investor fanbase grief and consternation.
- The article says there is no visibility into Abivax’s actual sale process, making it impossible to pinpoint exactly what is happening with the company and its Big Pharma suitors.
- The article presents the explanation that Abivax is French and therefore was not working in August as a facile possibility, not a confirmed explanation.
Why it matters: For Abivax investors, the gap between expectation and execution is central: a roughly $20 billion takeout had been considered likely any day nine months into the year, yet no transaction is visible and the sale process remains undisclosed. The immediate tension is blockbuster potential versus an acquisition that has not materialized.
Ask SkimNews
